Skip to content
Search

Latest Stories

India’s Trade Deficit Narrows to Five-Month Low of £10.62 Billion in September

India’s trade deficit declined to a five-month low of £10.62 billion in September 2018 despite jumping crude oil prices in the international market, said India’s Ministry of Commerce and Industry on Monday (15).

Country’s trade deficit during the first half of the financial year 2018-19 stood at £71.66bn. The exports for the month of September went down by 2.2 per cent while the imports recorded a jump of 10.5 per cent over the last fiscal year.


“Mid-year assessment shows exports growing in a healthy manner, building on export growth seen in 2016-17 and 2017-18,” the ministry said in a statement.

In the first half of the current fiscal year, the trade deficit came in at £71.66bn with exports up by 12.5 per cent and imports witnessing a rise of 16.2 per cent.

Imports during April-September 2018 period exhibited a positive growth of 16.16 per cent in dollar terms whereas, in September 2018, imports moved up 10.45 per cent in dollar terms, lowest in the last five months, the latest figures from the ministry added.

During September 2018, major commodity groups showing positive export growth over the corresponding month of last year are petroleum products (26.8 per cent), organic and inorganic chemicals (16.9 per cent), drugs and pharmaceuticals (3.8 per cent), cotton yarn, made-ups, handloom products, and others (3.6 per cent) and plastic, linoleum (28.2 per cent), the ministry said.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less